Nebenwirkungen · Duaklir Genuair
Duaklir Genuair 340 micrograms /12 micrograms inhalation powder · Abschnitt 4.8 · PDF-Seite 5
HOS-131030 · Präparat HOS-096989
The Duaklir Genuair clinical development programme was conducted in patients with moderate or severe COPD. A total of 1222 patients were treated with Duaklir Genuair 340 micrograms /12 micrograms. The frequencies assigned to the adverse reactions are based on crude incidence rates observed with Duaklir Genuair 340 micrograms /12 micrograms in the pooled analysis of randomised, placebo-controlled Phase III clinical studies of at least six months duration, or on experience with individual components or on post-marketing study results. The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from available data). System organ class Preferred term Frequency
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T17:43:00Z · SHA-256 738d2adbd3dbff6f1351d068e555e9581680fef31b44535569ea13bcee8ad9c8 · Passage 94c150645d3dc27785732038f28462cd2bd98805c860b2c564250481f67b2ccf · Zeichen 759–1649 im Abschnitt